EGFR and non-small cell lung carcinoma: The double-blind phase III randomized placebo-controlled KEYNOTE-407 and KEYNOTE-189 trials evaluated the combination of pembrolizumab with platinum-based chemotherapy in advanced squamous NSCLC and nonsquamous NSCLC without EGFR or ALK alterations, respectively.